$ANIX
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. It has a collaboration agreement with MolGenie GmbH to discover and develop anti-viral drug candidates against COVID-19. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.
Healthcare
Sector
Biotechnology
Industry
Amit Kumar
CEO
5
Employees
$2.93
Current Price
$94.13M
Market Cap
Insider Activity Statistics
Aggregated buying and selling activity by time period
| Period | Type | Insiders | Transactions | Value | Shares | Buy/Sell Ratio |
|---|---|---|---|---|---|---|
| 1 week | Buys | 2 | 2 | $45,600.00 | 16,000 | All Buys |
| Sells | 0 | 0 | - | - | ||
| 2 weeks | Buys | 2 | 2 | $45,600.00 | 16,000 | All Buys |
| Sells | 0 | 0 | - | - | ||
| 1 month | Buys | 3 | 3 | $61,220.00 | 21,500 | All Buys |
| Sells | 0 | 0 | - | - | ||
| 2 months | Buys | 4 | 9 | $275,736.84 | 100,536 | All Buys |
| Sells | 0 | 0 | - | - | ||
| 3 months | Buys | 4 | 10 | $293,086.84 | 105,536 | All Buys |
| Sells | 0 | 0 | - | - | ||
See activity going back 12 months โ create a free account | ||||||
Insider Transactions
Recent purchases and sales by company insiders
| Date | Insider | Type | Shares | Price | Value | Actions |
|---|---|---|---|---|---|---|
| Oct 23, 2026 | Titterton Lewis H jr Director | Purchase | 8,000 | $2.98 | $23,840.00 | View Details |
| Oct 22, 2026 | KUMAR AMIT Director | Purchase | 8,000 | $2.72 | $21,760.00 | View Details |
| Sep 30, 2026 | Catelani Michael President, COO,&CFO | Purchase | 5,500 | $2.84 | $15,620.00 | View Details |
| Sep 24, 2026 | KUMAR AMIT Director | Purchase | 7,000 | $2.78 | $19,460.00 | View Details |
| Sep 24, 2026 | Baskies Arnold M Director | Purchase | 5,000 | $2.76 | $13,800.00 | View Details |
| Sep 23, 2026 | Titterton Lewis H jr Director | Purchase | 49,036 | $2.69 | $131,906.84 | View Details |
| Sep 10, 2026 | KUMAR AMIT Director | Purchase | 3,000 | $2.75 | $8,250.00 | View Details |
| Sep 10, 2026 | Titterton Lewis H jr Director | Purchase | 10,000 | $2.73 | $27,300.00 | View Details |
| Sep 10, 2026 | KUMAR AMIT Director | Purchase | 5,000 | $2.76 | $13,800.00 | View Details |
| Jul 31, 2026 | KUMAR AMIT Director | Purchase | 5,000 | $3.47 | $17,350.00 | View Details |
| Jul 27, 2026 | KUMAR AMIT Director | Purchase | 5,000 | $3.44 | $17,200.00 | View Details |
| Jul 27, 2026 | KUMAR AMIT Director | Purchase | 3,188 | $3.37 | $10,743.56 | View Details |
8 more transactions available โ create a free account to see 12 months of history | ||||||
Upcoming Earnings
Scheduled earnings reports
No upcoming earnings scheduled
Past Earnings
Historical earnings results
EPS
Estimated-$0.08
Actual-$0.08
Beat
Revenue
EstimatedN/A
ActualN/A
5 more earnings records available โ create a free account to see 12 months of history
Related Activity
Cross-company insider connections and cluster buy signals
Insiders Also Active At
Insiders at this company also hold positions or have traded at these companies: